Consistently with this observation, our research group has previously demonstrated in xenotransplants of endocrine-resistant cell lines and patient-derived tumor cells (PDCs) isolated from breast carcinomas that the effect of PI3K inhibitors is independent of the presence of PIK3CA mutations24. Here, PIK3CA is linked to breast carcinoma.